Open Access

FKBP51 induces p53‑dependent apoptosis and enhances drug sensitivity of human non‑small‑cell lung cancer cells

  • Authors:
    • Yu Chen
    • Zhiqiang Liu
    • Yuequn Wang
    • Jian Zhuang
    • Yun Peng
    • Xiaoyang Mo
    • Jimei Chen
    • Yan Shi
    • Mengxiong Yu
    • Wanwan Cai
    • Yahuan Li
    • Xiaolan Zhu
    • Wuzhou Yuan
    • Yongqing Li
    • Fang Li
    • Zuoqiong Zhou
    • Guo Dai
    • Xiangli Ye
    • Yongqi Wan
    • Zhigang Jiang
    • Ping Zhu
    • Xiongwei Fan
    • Xiushan Wu
  • View Affiliations

  • Published online on: January 14, 2020     https://doi.org/10.3892/etm.2020.8450
  • Pages: 2236-2242
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lung cancer is one of the most prevalent cancer types worldwide, and non‑small‑cell lung cancer (NSCLC) accounts for ~85% of all lung cancer cases. Despite the notable prevalence of NSCLC, the mechanisms underlying its progression remain unclear. The present study investigated the involvement of FK506‑binding protein 51 (FKBP51) in NSCLC development and determined the factors associated with FKBP51 modification for NSCLC treatment. Immunohistochemical analysis was performed to analyze FKBP51 expression in human NSCLC tissue samples. Additionally, flow cytometry was performed to observe the apoptosis of FKBP51‑overexpressing A549 cells. A dual‑luciferase reporter assay was performed to confirm the association between FKBP51 and p53 expression, and western blotting was performed to analyze the effects of FKBP51 on the p53 signaling pathway. Finally, cell viability was measured using a Cell Counting Kit‑8 assay. The results suggested FKBP51 downregulation in human lung cancer. Furthermore, apoptosis rates may be increased in FKBP51‑overexpressing A549 cells. Moreover, FKBP51 promoted p53 expression and subsequent p53 signaling pathway activation. These results indicated that FKBP51 promoted A549 cell apoptosis via the p53 signaling pathway. Additionally, FKBP51 enhanced the sensitivity of A549 cells to cisplatin. Collectively, these data suggested that FKBP51 could serve as a biomarker for human lung cancer and can thus be tailored for incorporation into NSCLC therapy in the future.
View Figures
View References

Related Articles

Journal Cover

March 2020
Volume 19 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Chen, Y., Liu, Z., Wang, Y., Zhuang, J., Peng, Y., Mo, X. ... Wu, X. (2020). FKBP51 induces p53‑dependent apoptosis and enhances drug sensitivity of human non‑small‑cell lung cancer cells. Experimental and Therapeutic Medicine, 19, 2236-2242. https://doi.org/10.3892/etm.2020.8450
MLA
Chen, Y., Liu, Z., Wang, Y., Zhuang, J., Peng, Y., Mo, X., Chen, J., Shi, Y., Yu, M., Cai, W., Li, Y., Zhu, X., Yuan, W., Li, Y., Li, F., Zhou, Z., Dai, G., Ye, X., Wan, Y., Jiang, Z., Zhu, P., Fan, X., Wu, X."FKBP51 induces p53‑dependent apoptosis and enhances drug sensitivity of human non‑small‑cell lung cancer cells". Experimental and Therapeutic Medicine 19.3 (2020): 2236-2242.
Chicago
Chen, Y., Liu, Z., Wang, Y., Zhuang, J., Peng, Y., Mo, X., Chen, J., Shi, Y., Yu, M., Cai, W., Li, Y., Zhu, X., Yuan, W., Li, Y., Li, F., Zhou, Z., Dai, G., Ye, X., Wan, Y., Jiang, Z., Zhu, P., Fan, X., Wu, X."FKBP51 induces p53‑dependent apoptosis and enhances drug sensitivity of human non‑small‑cell lung cancer cells". Experimental and Therapeutic Medicine 19, no. 3 (2020): 2236-2242. https://doi.org/10.3892/etm.2020.8450